310 AI uses generative AI on AMD GPUs to design new therapeutics on—real drug candidates now heading from lab to clinic, all powered by MP4.

Accelerating Drug Discovery with AI: How 310 AI is Building the Future of Therapeutics

Can AI design life-saving therapeutics? At Beyond CUDA Summit 2025, Kooshiar Azimian, Founder & CEO of 310 AI, delivered one of the most compelling talks of the event—showing how generative AI, supercharged by AMD GPUs, is now tackling biology at scale.









🧠 Protein Design Is the New Frontier

Forget text and image generation—310 AI is pushing the boundaries of generative biology.

 * Prompt in, protein out: Their proprietary model turns natural language biological descriptions into compl

Can AI design life-saving therapeutics? At Beyond CUDA Summit 2025, Kooshiar Azimian, Founder & CEO of 310 AI, delivered one of the most compelling talks of the event—showing how generative AI, supercharged by AMD GPUs, is now tackling biology at scale.









🧠 Protein Design Is the New Frontier

Forget text and image generation—310 AI is pushing the boundaries of generative biology.

 * Prompt in, protein out: Their proprietary model turns natural language biological descriptions into complex 3D protein structures.
 * Why it matters: Proteins underpin every drug we use today. The therapeutic protein market is worth $300B+, with massive implications for diseases like cancer, diabetes, and more.

Azimian compared today’s stage of protein generation to the GAN days of 2014—early, imperfect, but promising.


🧪 Meet MP4: Molecule Programming, 4th Gen

310 AI’s MP4 model is a generative evolution of AlphaFold. Rather than predicting structure from sequence, it designs proteins end-to-end.

🔢 Training Details:

 * 300M+ sequences, 5B+ data points
 * Trained on AMD MI250 and MI300X GPUs using ROCm
 * Peaked at 200 sequences/second throughput
 * Completed over 72K GPU hours in training

⚙️ Engineering wins:

 * Switched from Nvidia A100 → H100 → MI250 → MI300X
 * ROCm migration took one engineer, one day
 * Tools like Cursor enabled fast porting


🔬 Real-World Results: From Code to Clinic

MP4 isn’t just theoretical—it’s producing lab-validated drugs.

In the past 90 days alone, 310 AI generated 96 GLP-1 analogs, a class of promising diabetes and weight loss therapeutics.

Expressed with 84% success in Swiss labs—significantly outperforming historical benchmarks.

Clinical testing begins next month.


🛠️ Why ROCm Matters for AI Biology

Transitioning from Nvidia to AMD is no longer a blocker.

310 AI’s experience shows that modern AI dev tools + ROCm = smooth scaling.

💡 Takeaways:

 * Training performance matched or exceeded Nvidia counterparts
 * Minimal code refactoring required
 * AMD MI300X enables faster iteration at lower cost


🔁 Final Thoughts: AI Isn’t Just Generating Text Anymore—It’s Generating Medicine

Azimian’s closing words hit home:

“If you can train a vision model, you can train a biology model.”

310 AI’s MP4 is proof that the future of drug discovery lies at the intersection of AI, high-performance compute, and domain expertise.

📺 Watch the full session: Accelerating Drug Discovery with Kooshiar Azimian | Beyond CUDA Summit 2025


🚀 Run Efficient Models on AMD GPUs

Deploy your optimized models on TensorWave’s AMD-powered AI cloud—built for training, inference, and experimentation at scale on MI300X and MI325X GPUs.


About TensorWave

TensorWave is the AI and HPC cloud purpose-built for performance. Powered exclusively by AMD Instinct™ Series GPUs, we deliver high-bandwidth, memory-optimized infrastructure that scales with your most demanding models—training or inference.

Ready to get started? Connect with a Sales Engineer.

TensorWave Welcomes the AMD Instinct™ MI355X

Accelerating Drug Discovery with AI: How 310 AI is Building the Future of Therapeutics

Subscribe to our Blog

Stay ahead of the curve with the latest in AI, AMD accelerators, and all things TensorWave.

Product

Resources

Company

© 2025 TensorWave Inc. - All rights reserved.